10-Q: Launch One Q3 2025: Minovia Merger Progress, Liquidity Concerns

Launch One Acquisition Corp. reports Q3 2025 net income of $2.01M, progresses Minovia merger, but faces significant liquidity and going concern doubts.

Summary

• Reported net income of $2,011,042 for the three months ended September 30, 2025, and $6,220,473 for the nine months ended September 30, 2025.
• Cash and marketable securities held in the Trust Account totaled $243,082,744 as of September 30, 2025.
• The company has entered into a definitive Business Combination Agreement with Minovia Therapeutics Ltd., which was amended on August 12, 2025.
• The merger consideration for Minovia security holders is $180 million plus aggregate net cash proceeds from Minovia's financing activities, payable in Pubco ordinary shares.
• An earnout of an additional $57.5 million in Pubco ordinary shares is contingent on Pubco's share price reaching $11.50 or Minovia initiating a Phase 3 clinical trial within five years post-closing.
• A Minimum Cash Condition of $23 million is required for the closing of the Minovia Business Combination.
• The company had a working capital deficit of $332,033 as of September 30, 2025.
• Management has determined that there is substantial doubt about the company's ability to continue as a going concern due to liquidity issues and the mandatory liquidation date of July 15, 2026, if a Business Combination is not completed.
• Minovia is seeking Bridge Financing of at least $5 million at a $120 million pre-money equity valuation, and additional Transaction Financing of at least $18 million.

Sentiment

Score: 4

Explanation: While the company is progressing with its business combination, significant liquidity issues and a stated going concern doubt, coupled with increased expenses and a decline in quarterly net income compared to the prior year, indicate a challenging financial position. The reliance on future financing and the successful completion of the merger to resolve these issues adds considerable uncertainty.

Positives

• The Trust Account continues to generate significant interest income, totaling $2,556,473 for the three months and $7,553,223 for the nine months ended September 30, 2025.
• Progress has been made on the Minovia Business Combination, with a definitive agreement in place and an amendment executed to facilitate the transaction.
• The company's disclosure controls and procedures were evaluated and concluded to be effective as of September 30, 2025.

Negatives

• The company reported a working capital deficit of $332,033 as of September 30, 2025.
• Management has determined that the company currently lacks the liquidity to sustain operations for a reasonable period and has raised substantial doubt about its ability to continue as a going concern.
• Net income for the three months ended September 30, 2025 ($2,011,042), was lower than the $2,605,302 reported for the same period in 2024.
• General and administrative expenses increased significantly to $517,261 for Q3 2025 from $189,929 for Q3 2024.
• The company recorded an unrealized loss on marketable securities held in the Trust Account of $28,221 for Q3 2025, compared to an unrealized gain of $388,318 for Q3 2024.

Risks

• Inability to successfully consummate the Minovia Business Combination by July 15, 2026, which would lead to mandatory liquidation and redemption of Public Shares.
• The proceeds deposited in the Trust Account could become subject to claims of the company's creditors, potentially having priority over the claims of Public Shareholders.
• The Sponsor's ability to satisfy its indemnification obligations to the company is not assured, as its only assets are believed to be company securities.
• Failure to meet the Nasdaq 36-Month Requirement could result in the suspension of trading and delisting from Nasdaq.
• The company's lack of liquidity to sustain operations for a reasonable period raises substantial doubt about its ability to continue as a going concern.
• There is no assurance that new financing (e.g., Working Capital Loans, Bridge Financing, Additional Transaction Financing) will be available on commercially acceptable terms, if at all.
• The ability to complete a Business Combination may be adversely affected by various factors beyond the company's control, including changes in laws/regulations, financial market downturns, economic conditions, inflation, interest rates, tariffs, supply chain disruptions, public health considerations, and geopolitical instability.
• Risks related to Minovia and the Minovia Business Combination will be detailed in the Minovia Registration Statement once filed.
• A freedom to operate (FTO) analysis could conclude that Minovia's products or technology are reasonably likely to materially infringe third-party U.S. Patents, potentially leading to termination of the Business Combination Agreement if a commercially reasonable mitigation plan is not proposed and accepted.

Future Outlook

The company intends to complete the Minovia Business Combination before the end of the Combination Period, which is July 15, 2026. Upon consummation, Pubco will become a publicly traded company with its ordinary shares listed on Nasdaq. Minovia is actively seeking bridge financing of at least $5 million and additional transaction financing of at least $18 million to support the combined entity. The post-closing Pubco board of directors will consist of eight members, with a majority qualifying as independent under Nasdaq rules.

Management Comments

• Management plans to address the uncertainty regarding the company's ability to continue as a going concern through a Business Combination.
• There can be no assurance that new financing will be available to the company on commercially acceptable terms, if at all.
• Management plans to consummate an initial Business Combination prior to the end of the Combination Period.

Industry Context

Launch One Acquisition Corp. operates as a Special Purpose Acquisition Company (SPAC) in the de-SPAC phase, aiming to merge with Minovia Therapeutics Ltd., a biotechnology company. The challenges highlighted, such as the need for additional financing, the strict timeline for completing a business combination (July 15, 2026), and the Nasdaq 36-Month Requirement, are typical for SPACs navigating the merger process. The target, Minovia, is engaged in clinical development programs, placing the combined entity in the capital-intensive and high-risk biotechnology sector, where successful clinical trials are critical for valuation and future growth.

Legal Proceedings

• No material litigation currently pending or contemplated against the company, its officers, or directors.

Related Party Transactions

• The Sponsor made a capital contribution of $25,000 for 5,750,000 Class B Ordinary Shares (Founder Shares).
• The Sponsor and Cantor purchased 6,000,000 Private Placement Warrants for $6,000,000.
• The Sponsor loaned the company up to $340,000 via an IPO Promissory Note, which was repaid.
• The company has an outstanding amount of $27,340 due from the Sponsor, representing an excess payment on the IPO Promissory Note.
• An Administrative Services Agreement with an affiliate of the Sponsor requires monthly payments of $12,500 for office space, utilities, and administrative support.
• The Sponsor or an affiliate of the Sponsor or certain officers and directors may provide Working Capital Loans to the company.
• The Sponsor agreed to subject 22.5% of its Founder Shares (Sponsor Earnout Shares) to transfer restrictions and potential forfeiture based on earnout conditions.

Stakeholder Impact

• **Shareholders (Public)**: Face potential for redemption at approximately $10.56 per share if the Business Combination is not completed, but also risk of liquidation if the merger fails. Their investment is largely protected within the Trust Account.
• **Shareholders (Sponsor/Founder)**: Their Founder Shares are subject to lock-up periods and potential forfeiture based on earnout conditions, aligning their interests with the long-term success of the combined entity.
• **Minovia Security Holders**: Will receive consideration in Pubco ordinary shares and have contingent rights to additional Earnout Shares, tying their future value to the performance of the combined company.
• **Underwriters**: Are entitled to a deferred underwriting fee of $10,950,000 upon the successful completion of the Business Combination.
• **Creditors**: The Trust Account proceeds could potentially be subject to creditor claims, which might have priority over Public Shareholders' claims under certain circumstances.
• **Employees (Minovia Management)**: Expected to enter into new employment agreements with Pubco post-merger, indicating continuity and integration plans.

Next Steps

• Consummate the Minovia Business Combination before July 15, 2026.
• Minovia to seek, enter into, and consummate Bridge Financing of at least $5 million within 60 days after the execution of the Minovia BCA.
• The company, Minovia, and Pubco to use commercially reasonable efforts to enter into Additional Transaction Financing agreements for aggregate proceeds of at least $18 million.
• File a Registration Statement on Form F-4 (Minovia Business Combination Registration Statement) with the SEC.
• Obtain Company and Minovia shareholder approvals for the Business Combination.
• Obtain Nasdaq approval for the listing of Pubco ordinary shares.
• Appoint the post-Closing Pubco board of directors, consisting of eight directors.
• Amend and restate Pubco's organizational documents.
• Enter into an amendment and restatement of the Registration Rights Agreement to have Pubco assume registration obligations.
• Receive certain employment agreements between Pubco and Minovia management.
• Receive Lock-Up Agreements from certain Minovia security holders.
• Receive certain Israeli tax rulings and Israeli securities laws rulings.
• Conclude statutory merger waiting periods under Israeli law.
• Form SPAC Merger Sub and have it execute a joinder agreement to the Minovia BCA.
• The company agreed to deliver PCAOB audited annual financial statements for 2024 and PCAOB reviewed interim financial statements for the nine-month period ended September 30, 2025.
• The company will use commercially reasonable efforts to perform a freedom to operate (FTO) analysis for Minovia's products and technology.

Key Dates

Recommendation

The company is a SPAC in the critical de-SPAC phase, with a definitive agreement to merge with Minovia Therapeutics. While the Trust Account provides a floor for public shareholders, the company faces significant liquidity challenges and a stated 'going concern' doubt, which are serious red flags. The success of the merger is contingent on several factors, including additional financing for Minovia and regulatory approvals, and the future performance of the combined biotechnology entity is inherently risky. A 'hold' recommendation reflects the binary nature of this investment: potential upside if the merger closes and Minovia performs well, balanced against the downside protection offered by the Trust Account value if the merger fails, but with considerable uncertainty regarding the path to closing and the post-merger outlook.

Keywords

SPAC, Minovia Therapeutics, Business Combination, 10-Q, Quarterly Report, SEC Filing, Launch One Acquisition Corp, De-SPAC, Merger, Biotechnology, Clinical Trials, Nasdaq, Trust Account, Going Concern, Liquidity, Warrants, Financials